ArticleJournal of the International Neuropsychological Society : JINS2022
Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment.
Open access · greenAbstract read
In one paragraph
Article in Journal of the International Neuropsychological Society : JINS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review.Journal of neurology · 2024Pooled it
- Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.Neurology · 2024Pooled it
- SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis.BMC neurology · 2023Pooled it
- Article
- Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly.bioRxiv : the preprint server for biology · 2026Article
- Blood-based biomarkers GFAP/UCH-L1 for the diagnosis of mild traumatic brain injury (mTBI): a single-center implementation experience.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026Article
- Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.medRxiv : the preprint server for health sciences · 2026Article
- White Matter Hyperintensities in Behavioral Variant Frontotemporal Dementia and Semantic Variant Primary Progressive Aphasia.Neurology open access · 2026Article
- When Alzheimer's pathology meets cardiometabolic risk: intrinsic subcortical-cortical connectivity signatures of retroactive interference in aging.Alzheimer's research & therapy · 2026Article
- Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.Brain communications · 2026Article
- The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer's Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression.Molecular neurobiology · 2025Review
- AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Physical frailty and MRI markers of structural brain integrity in the community-dwelling late middle-aged and old adults.Scientific reports · 2025Article
- The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort.The journal of prevention of Alzheimer's disease · 2025Article
- Deciphering the Structural Biology of GFAP: Connotations of Its Potency in Presaging the Diagnosis for Traumatic Brain Injury and AD.Neurology international · 2025Review
- Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis.IBRO neuroscience reports · 2025Review
- Microglial activation as a hallmark of neuroinflammation in Alzheimer's disease.Metabolic brain disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Breton M AskenDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.ORCID 0000-0001-8419-142X
Lawren VandeVredeDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Julio C RojasDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Corrina FonsecaDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Adam M StaffaroniDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Fanny M ElahiDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Cutter A LindberghDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.ORCID 0000-0002-9329-4663
Alexandra C AppleDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Michelle YouDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Sophia Weiner-LightDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Nivetha BrathabanDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Nicole FernandesDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Adam L BoxerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Bruce L MillerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Howie J RosenDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Joel H KramerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Kaitlin B CasalettoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
University of California, San Francisco · US
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Serggio Carlo Lanata · 2019 to 2026
$36.9MThe Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1MMechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3MTraining - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4MBiological Predictors Of Brain Aging Trajectories Diversity Supplement: African American Outreach And The Intersection Between Social Determinants Of Health And Biomarkers Of Degenerative DiseaseRF1AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2020 to 2021
$5.3MNovel imaging and endothelial biomarkers of small vessel cerebrovascular diseaseUH3NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DECARLI, CHARLES, KRAMER, JOEL H · 2018 to 2020
$3.5MEffects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2MNovel Imaging and Biofluid Biomarkers of Small Vessel Cerebrovascular DiseaseUF1NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2021 to 2021
$2.5MMultimodal Imaging in Frontotemporal DegenerationK24AG045333 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2013 to 2023
$1.9MCSRD VA IK2 CX002180NIA NIH HHS K23 AG031861NIA NIH HHS K23 AG058752NIA NIH HHS K23 AG059888NIA NIH HHS K23 AG061253NIA NIH HHS K23 AG073514NIA NIH HHS K24 AG045333NIA NIH HHS L30 AG069301NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG048234NIA NIH HHS RF1 AG032289NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NINDS NIH HHS U54 NS092089NINDS NIH HHS UF1 NS100608NINDS NIH HHS UH3 NS100608
Abstract
objectiveThere are minimal data directly comparing plasma neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in aging and neurodegenerative disease research. We evaluated associations of plasma NfL and plasma GFAP with brain volume and cognition in two independent cohorts of older adults diagnosed as clinically normal (CN), mild cognitive impairment (MCI), or Alzheimer's dementia.
methodsWe studied 121 total participants (Cohort 1:
resultsHigher plasma GFAP was associated with lower white matter volume in both cohorts for temporal (Cohort 1:
conclusionsPlasma GFAP may be more sensitive to white matter and cognitive changes than plasma NfL. Biomarkers reflecting astroglial pathophysiology may capture complex dynamics of aging and neurodegenerative disease.
Indexed as
Alzheimer DiseaseCognitive DysfunctionNeurodegenerative DiseasesWhite MatterAgedAged, 80 and overBiomarkersExecutive FunctionGlial Fibrillary Acidic ProteinHumansIntermediate FilamentsMiddle AgedNeurofilament ProteinsBiomarkersGlial Fibrillary Acidic ProteinNeurofilament ProteinsAgingAlzheimer’sAstrocyteBiomarkersDementiaGlial fibrillary acidic protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.